A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer

Trial Profile

A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Apr 2018

At a glance

  • Drugs Folate-fluorescein isothiocyanate conjugate (Primary)
  • Indications Ovarian cancer
  • Focus Diagnostic use; Registrational
  • Sponsors On Target Laboratories
  • Most Recent Events

    • 05 Apr 2018 According to an On Target Laboratories media release, first patient has been treated in this study and top-line data from this study are expected in 2019.
    • 26 Jan 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Oct 2018.
    • 26 Jan 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top